195 related articles for article (PubMed ID: 756166)
1. Self-inhibitory dopamine-receptors and central effects of apomorphine.
Di Chiara G; Porceddu ML; Morelli M; Gessa GL
Ann Ist Super Sanita; 1978; 14(1):111-22. PubMed ID: 756166
[TBL] [Abstract][Full Text] [Related]
2. Behavioural effects of drugs acting on the central dopaminergic neurons.
Georgiev V; Markovska V
Act Nerv Super (Praha); 1977 Jul; 19 Suppl 2():335-6. PubMed ID: 575925
[No Abstract] [Full Text] [Related]
3. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.
Imperato A; Tanda G; Frau R; Di Chiara G
J Pharmacol Exp Ther; 1988 Apr; 245(1):257-64. PubMed ID: 3258912
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine as a preferential stimulant of self-inhibitory dopamine receptors in man.
Corsini GU; Del Zompo M; Piccardi MP; Mangoni A; Gessa GL
Ann Ist Super Sanita; 1978; 14(1):123-30. PubMed ID: 756167
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiological evaluation of a partial agonist of dopamine receptors.
Piercey MF; Hoffmann WE; Vogelsang GD; Travis M
J Pharmacol Exp Ther; 1987 Oct; 243(1):391-6. PubMed ID: 3668865
[TBL] [Abstract][Full Text] [Related]
7. The involvement of serotonin in the mechanism of central action of apomorphine.
Grabowska M
Pol J Pharmacol Pharm; 1976; 28(4):389-94. PubMed ID: 790347
[TBL] [Abstract][Full Text] [Related]
8. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
9. Studies on the participation of the dopaminergic system in the central effects of chelidonine.
Kleinrok Z; Szponar J; Matuszek B; Jagiełło-Wójtowicz E
Pol J Pharmacol Pharm; 1990; 42(5):417-24. PubMed ID: 2098751
[TBL] [Abstract][Full Text] [Related]
10. Sleep induced by low doses of apomorphine in rats.
Mereu GP; Scarnati E; Paglietti E; Quarantotti BP; Chessa P; Di Chiara G; Gessa GL
Electroencephalogr Clin Neurophysiol; 1979 Feb; 46(2):214-9. PubMed ID: 86429
[TBL] [Abstract][Full Text] [Related]
11. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
Breese GR; Napier TC; Mueller RA
J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
[TBL] [Abstract][Full Text] [Related]
12. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
13. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
[TBL] [Abstract][Full Text] [Related]
14. Effects of dopamine, apomorphine gamma-hydroxybutyric acid, haloperidol and pimozide on reflex bradycardia in rats.
Chen FF; Lin MT
J Pharmacol Exp Ther; 1980 Aug; 214(2):427-32. PubMed ID: 7391987
[TBL] [Abstract][Full Text] [Related]
15. Bromocriptine: a rather specific stimulant of dopamine receptors regulating dopamine metabolism.
Di Chiara G; Vargiu L; Porceddu ML; Gessa GL
Adv Biochem Psychopharmacol; 1977; 16():443-6. PubMed ID: 578073
[No Abstract] [Full Text] [Related]
16. Pimozide: delayed onset of action at rat striatal pre- and postsynaptic dopamine receptors.
McMillen BA; German DC; Sanghere MK; Warnack W; Shore PA
J Pharmacol Exp Ther; 1980 Oct; 215(1):150-5. PubMed ID: 6109013
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
Meltzer LT; Caprathe BW; Christoffersen CL; Corbin AE; Jaen JC; Ninteman FW; Pugsley TA; Serpa KA; Shih YH; Whetzel SZ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies.
Wachtel SR; White FJ
J Pharmacol Exp Ther; 1988 Jan; 244(1):410-6. PubMed ID: 2891845
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic and cholinergic influences on motor behavior in chickens.
Sanberg PR
J Comp Psychol; 1983 Mar; 97(1):59-68. PubMed ID: 6872506
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic influence on the effects of angiotensin II in behavioural reactions.
Georgiev V; György L; Yonkov D; Getova D; Markovska V; Petkova B
Physiol Bohemoslov; 1985; 34 Suppl():45-8. PubMed ID: 3014581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
